Kalaris Therapeutics
KLRS
84 hedge funds and large institutions have $110M invested in Kalaris Therapeutics in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 12 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
0.05% more ownership
Funds ownership: 1.81% → 1.87% (+0.05%)
0% more funds holding
Funds holding: 84 → 84 (0)
40% less capital invested
Capital invested by funds: $184M → $110M (-$74.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$9.12M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$3.43M |
| 3 |
Renaissance Technologies
New York
|
+$1.13M |
| 4 |
BlackRock
New York
|
+$1.13M |
| 5 |
State Street
Boston,
Massachusetts
|
+$661K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.72M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.41M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.87M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$580K |
| 5 |
Millennium Management
New York
|
-$572K |
KLRS Hedge Fund Activity: Q2 2022 in Review
84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2022, worth a combined $110M — down 40% from $184M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KLRS positions and 12 closed out — a net gain of 2 holders — while 30 added to existing stakes and 22 trimmed.
The largest buyer was Alkeon Capital Management, adding an estimated $9.12M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.72M sold.
- 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $110M of Kalaris Therapeutics stock for Q2 2022, down 40% quarter-over-quarter.
- 14 funds opened new Kalaris Therapeutics positions in Q2 2022 and 12 closed out, a net change of +2 holders.
- The largest Kalaris Therapeutics buyer in Q2 2022 was Alkeon Capital Management, an estimated $9.12M added.
- The largest Kalaris Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $9.72M sold.
Based on aggregated 13F filings for Q2 2022.